Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abbreviated BrECADD in Stage 2B-IV Hodgkin Lymphoma
NCT07002216Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2025
- Primary completion
- Jul 2030
- Countries
- 1
- Sponsor
- University of Miami
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Drugs
- brentuximab vedotin
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by University of Miami. Primary endpoint: Progression-free survival at 12 months. Started Jul 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
BrECADD
Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, Dexamethasone
03
Who it enrols
Adult patients (18-60) with newly diagnosed Stage 2B, 3, or 4 classical Hodgkin Lymphoma, adequate organ function, and no prior systemic therapy.
04
Endpoints
Primary
Progression-free survival
Secondary
Progression-free survival
Number of Treatment-Related Adverse Events
Number of Treatment-Related Serious Adverse Events
Percentage of Participants With Toxicity Throughout BrECADD Measured by PRO-CTCAE
Percentage of Participants With Toxicity Throughout BrECADD measured by FRAIL
Beyond the preview
Go deeper on NCT07002216.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002216.